Эффективность и безопасность антидепрессивных и седативных средств растительного происхождения


Ушкалова А.В., Илларионова Т.С.

Рассматриваются возможности применения лекарственных средств растительного происхождения для лечения разнообразных нервно-психических расстройств. Многие из растительных препаратов были изучены в рандомизированных контролируемых исследованиях, продемонстрировав выраженную клиническую эффективность и хорошую переносимость. К их числу, в частности, относятся экстракт зверобоя, валериана, мята перечная и мелисса, которые нередко применяются в различных комбинациях. К их числу относится комбинация валерианы, мелиссы лимонной и мяты перечной, выпускаемой в виде препарата Персен. Представлены результаты клинических исследований Персена, позволяющие рекомендовать его применение при невротических расстройствах, сопровождающихся тревогой, астенией, вегетативными дисфункциями, нарушением сна, а также при психовегетативных и посттравматических стрессовых расстройствах. Подчеркивается очень хорошая переносимость Персена.

Литература






  1. Prevalence of major psychiatric disorders in primary health care Goldberg DP, Lecrubier Y (1995). Form and frequency of mental disorders across centres. In: Ustun TB, Sartorius N, eds. Mental illness in general health care: an international study. Chichester, John Wiley & Sons on behalf of WHO: 323–334.

  2. Вознесенская Т.Г. Эмоциональный стресс и профилактика его последствий // РМЖ. 2006. Т. 14. № 9. С. 694–97.

  3. Kim HL, Streltzer J, Goebert D. St John's wort for depression: a meta-analysis of well-defined clinical trials. J Nerv Ment Dis 1999;187(9):532–38.

  4. Linde K, Ramirez G, Mulrow CD, et al. St John's wort for depression – an overview and meta-analysis of randomised clinical trials. BMJ 1996;313(7052):253–58.

  5. Volz HP. Controlled clinical trials of Hypericum extracts in depressed patients – an overview. Pharmacopsychiatry 1997;30(Suppl. 2):72–76.

  6. Whiskey E, Werneke U, Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review. Int Clin Psychopharmacol 2001;16 (5):239–52.

  7. American Psychiatric Association. Practice guidelines for the treatment of patients with panic disorder. Work Group on Panic Disorder. Am J Psychiatry 1998;155(Suppl. 5):1–34.

  8. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001;62(Suppl. 11):53–58.

  9. Pomerantz JM. Risk Versus Benefit of Benzodiazepines. Psychiatric Times 2007;24(7).

  10. Dugoua J-J, Mills E, Perri D, et al. Safety and efficacy of St. John's wort (hypericum) during pregnancy and lactation. Can J Clin Pharmacol 2006;13(3):e268–e276.

  11. Volz HP, Murck H, Kasper S, et al. St. John'swort extract (LI 160) in somatoform disorders:results of a placebo-controlled trial. Psychopharmacology (Berl) 2002;164:294–300.

  12. Brockmoller J, Reum T, Bauer S, et al. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997;30:S94–S101.

  13. Butterweck V. Mechanism of action of St John's wort in depression: what is known? CNS Drugs 2003;17(8):539–62.

  14. Boullata JI, Nace AM. Safety Issues with Herbal Medicine. Pharmacotherapy 2000;20(3): 257–69.

  15. Bent S, Padula A, Moore D, et al. Valerian for sleep: a systematic review and meta-analysis. Am J Med 2006;119(12):1005–12.

  16. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998;158:2200–11.

  17. Hrastinger A, Dietz B, Bauer R, et al. Is there clinical evidence supporting the use of botanical dietary supplements in children? J Pediatr 2005;146:311–17.

  18. Andreatini R, Sartori VA, Seabra ML, et al. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res 2002;16:650–54.

  19. Miyasaka LS, Atallah AN, Soares BG. Valerian for anxiety disorders. Cochrane Database Syst Rev 2006;(4):CD004515.

  20. Houghton PJ. The biological activity of valerian and related plants. J Ethnopharmacol 1988; 22:121–42.

  21. Ortiz JG, Nieves-Natal J, Chavez P. Effects of Valeriana officinalis extracts on[3H] flunitrazepam binding, synaptosomal [3H]GABA uptake, and hippocampal [3H]GABA release. Neurochem Res 1999;24:1373–78.

  22. Riedel E, Hansel R, Ehrke G. Inhibition of gamma-aminobutyric acid catabolism by valerenic acid derivatives. Planta Med 1982;46:219–20.

  23. Spinella M. The importance of pharmacological synergy in psychoactive herbal medicines. Altern Med Rev 2002;7(2):130–37.

  24. Panijel M. Treatment of moderately severe anxiety states. Therapiewoche 1985;35:4659–68.

  25. Carnat AP, Carnat A, Fraisse D, et al. The aromatic and polyphenolic composition of lemon balm (Melissa Officinalis L. subsp. Officinalis) tea. Pharm Acta Helvetiae 1998;72:301–305.

  26. Hohmann J, Zupko I, Redei D, et al. Protective effects of the aerial parts of Salvia Officinalis, Melissa Officinalis and Lavandula angustifolia and their constituents against enzyme-dependent and enzyme-independent lipid peroxidation. Planta Med 1999;65:576–78.

  27. Perry N, Court G, Bidet N, et al. European Herbs with cholinergic activities: potential in dementia therapy. Int J Geriatric Psychiatry 1996;11: 1063–69.

  28. Wake G, Court J, Pickering A, et al. CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. J Ethnopharmacol 2000;69:105–14.

  29. Hohmann J, Zupko I, Redei D, et al. Protective effects of the aerial parts of Salvia Officinalis, Melissa Officinalis and Lavandula angustifolia and their constituents against enzyme-dependent and enzyme-independent lipid peroxidation. Planta Med 1999;65:576–78.

  30. Mantle D, Eddeb F, Pickering A. Comparison of relative antioxidant activities of British medicinal plant species in vitro. J Ethnopharmacol 2000;72:47–51.

  31. Gundermann KJ, Godehardt E, Ulbrich M. Efficacy of a herbal preparation in patients with functional dyspepsia: A meta-analysis of double-blind, randomized, clinical trials. Advances in Therapy 2003;1:43.

  32. de Sousa AC, Alviano DS, Blank AF, et al. Melissa officinalis L. essential oil: antitumoral and antioxidant activities. J Pharm Pharmacol 2004;56 (5):677–81.

  33. Schulz V. Rational Phytotherapy: A Physicians' Guide to Herbal Medicine, ed 5. Berlin, Springer, 2004.

  34. Kennedy DO, Scholey AB. The psychopharmacology of European herbs with cognition-enhancing properties. Curr Pharm Des 2006;12 (35):4613–23.

  35. Kennedy DO, Scholey AB, Tildesley NTJ, et al. Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon Balm). Pharmacol Biochem Behav 2002;72:953–64.

  36. Kennedy DO, Little W, Scholey AB. Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (Lemon Balm). Psychosom Med 2004; 66 (4):607–13.

  37. Perry EK, Pickering AT, Wang WW, et al. Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. J Pharm Pharmacol 1999;51:527–34.

  38. Kennedy DO, Wake G, Savelev S, et al. Modulation of Mood and Cognitive Performance Following Acute Administration of Single Doses of Melissa officinalis (Lemon Balm) with Human CNS Nicotinic and Muscarinic Receptor-Binding Properties. Neuropsychopharmacology 2003;28: 1871–81.

  39. Akhondzadeh S, Noroozian M, Mohammadi M, et al. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial. J Neurol Neurosurg Psychiatry 2003;74(7):863–66.

  40. Ballard C, O'Brien J, Reichelt K, et al. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double blind, placebo controlled trial. J Clin Psychiatry 2002;63:553–58.

  41. Dos Santos-Neto LL, de Vilhena Toledo MA, Medeiros-Souza P, et al. The use of herbal medicine in Alzheimer's disease-a systematic review. Evid Based Complement Alternat Med 2006;3(4): 441–45.

  42. [No authors listed]. Management of insomnia: a place for traditional herbal remedies. Prescrire Int 2005;14(77):104–07.

  43. Cerny A, Schmid K. Tolerability and efficacy of valerian/lemon balm in healthy volunteers: a double-blind, placebo-controlled, multicentre study. Fitoterapia 1999;70:221–28.

  44. Dressing H, Riemann D, Low H, et al. Insomnia: are valerian/balm combination of equal value to benzodiazepine? Therapiewoche 1992;42: 726–36.

  45. Kennedy DO, Little W, Haskell CF, et al. Anxiolytic effects of a combination of Melissa officinalis and Valeriana officinalis during laboratory induced stress. Phytother Res 2006;20(2):96–102.

  46. Воробьева О.В. Психовегетативный синдром, ассоциированный с тревогой (вопросы диагностики и терапии) // РМЖ. 2006. Т. 14. № 23. С. 1696–1699.

  47. Фармацевтический вестник. 2 февраля 2007 г.

  48. Дворецкий Л.И. Соматоформные расстройства в практике терапевта // РМЖ 2002. Т. 10. № 19. С. 167–71.

  49. Вознесенская Т.Г., Федотова А.В., Фокина Н.М. Персен форте в лечении тревожных расстройств у больных психовегетативным синдромом // Медицинское лечение нервных болезней. С. 38–41.

  50. Попонникова Т.В., Пиневич О.С., Серговская В.Д. и др. Особенности терапии в остром периоде клещевых микст-инфекций с поражением нервной системы у детей и подростков. http://panavir.ru/php/content.php?id=1069.




Бионика Медиа